BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2819091)

  • 1. Urokinase binds to a plasminogen activator inhibitor type-2-like molecule in placental microvillous membranes.
    Jensen PH; Nykjaer A; Andreasen PA; Lund LR; Astedt B; Lecander I; Gliemann J
    Biochim Biophys Acta; 1989 Nov; 986(1):135-40. PubMed ID: 2819091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
    Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
    J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
    Wun TC; Reich E
    J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
    Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
    J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor.
    Chapman HA; Stone OL
    Biochem J; 1985 Aug; 230(1):109-16. PubMed ID: 2932100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of urokinase and thrombin in cultured neural cells.
    Wagner SL; Lau AL; Nguyen A; Mimuro J; Loskutoff DJ; Isackson PJ; Cunningham DD
    J Neurochem; 1991 Jan; 56(1):234-42. PubMed ID: 1987320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Collen D
    J Biol Chem; 1991 Mar; 266(7):4041-4. PubMed ID: 1900284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks].
    Uszyński W; Uszyński M
    Ginekol Pol; 2004 Dec; 75(12):971-8. PubMed ID: 15751221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
    Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
    Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and characterisation of plasminogen activator inhibitor 2 produced in Saccharomyces cerevisiae.
    Steven J; Cottingham IR; Berry SJ; Chinery SA; Goodey AR; Courtney M; Ballance DJ
    Eur J Biochem; 1991 Mar; 196(2):431-8. PubMed ID: 1901039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
    Jensen PH; Christensen EI; Ebbesen P; Gliemann J; Andreasen PA
    Cell Regul; 1990 Dec; 1(13):1043-56. PubMed ID: 1966892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures.
    Jensen PH; Lorand L; Ebbesen P; Gliemann J
    Eur J Biochem; 1993 May; 214(1):141-6. PubMed ID: 8099547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects.
    Bikfalvi A; Sauzeau C; Moukadiri H; Maclouf J; Busso N; Bryckaert M; Plouet J; Tobelem G
    J Cell Physiol; 1991 Oct; 149(1):50-9. PubMed ID: 1719003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative receptor assay using Triton X-114 for plasminogen activator binding proteins in solubilized membranes from human liver and placenta.
    Nguyen G; Kruithof EK
    Anal Biochem; 1993 Feb; 208(2):277-82. PubMed ID: 8383929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
    Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
    Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
    Holmberg L; Lecander I; Persson B; Astedt B
    Biochim Biophys Acta; 1978 Nov; 544(1):128-37. PubMed ID: 152655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.